Joshua M. Liao & Michael A. Fischer | Huffington Post
In the first year after the approval of sofosbuvir by the FDA, there was a rapid, widespread increase in Medicaid spending on sofosbuvir, but with substantial variation across states. READ MORE
Joshua M. Liao & Mark V. Pauly | Philadelphia Inquirer (Health Cents)
The outcry and scrutiny over drug pricing policies has amplified the national debate over high specialty drug costs. Not all high-priced drugs, however, are created equal. READ MORE
Source: NEJM 2015; 373:1279-1281.
Copyright 2016 © Joshua Liao. All rights reserved